


SARS-CoV-2 Sequencing Update **06 October 2023**



Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)

Department

Science and Innovation

REPUBLIC OF SOUTH AFRICA


The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 06 October 2023 at 09h45



Data license: https://www.gisaid.org/registration/terms-of-use/


Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101




GISAID genomes vs total cases, 2020 – 2023 (N= 53 577)

Provincial breakdown of genomes deposited into GISAID 14284 14500 Collected before Jan 2023 (total 14069 Collected Jan 2023 (total 1236) Collected Feb 2023 (total 1310) Collected Mar 2023 (total 763)






Number and percentage of clades by epiweek in South Africa, 2022-2023 (19 819*)



epiweeks in 2022 - 2023

Detection Rates: Omicron and recombinants




*Bars represent percentage prevalence of variant for the month; total number sequences collected for the month are given below the bar

Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in


July – September 2023

July (N=58)

September (N=71)



South Africa, 2022-2023, n = 19 819*




*Excludes sequences missing collection dates. Lineages of particular interest (mainly WHO Omicron subvariants under monitoring) are separate from the main clade groupings. #Recombinants include all recombinant lineages (viruses consisting of segments of two different lineages) detected in South Africa at low levels. Currently it consists of XT, XAS, XAZ, XBA, XBF. NGS-SA Network for Genomic Surveillance in South Africa

Eastern Cape Province, 2022-2023, n = 1084

Genomes added since last report: 1*

EC (N=1084)





*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.


XAY

XBF

Free State Province, 2022-2023, n = 663

Genomes added since last report: 3*

FS (N=663)





Surveillance in South Africa

*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

Gauteng Province, 2022-2023, n = 5855

Genomes added since last report: 87*







*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.


XAY

XBF

KwaZulu-Natal Province, 2022-2023, n = 2138

Genomes added since last report: 0*

KZN (N=2138)





*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.


XAY

XBF

Limpopo Province, 2022-2023, n = 945

Genomes added since last report: 0*








*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

Mpumalanga Province, 2022-2023, n = 1480

Genomes added since last report: 5*





*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.


XAY

XBF

Northern Cape Province, 2022-2023, n = 584

Genomes added since last report: 0*

NC (N=584)






*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

North West Province, 2022-2023, n = 727

Genomes added since last report: 5*

NW (N=727)






*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

Western Cape Province, 2022-2023, n = 6322

Genomes added since last report: 265*





*May include genomes from 2020 and 2021 which are not pictured here and are not included in the slide total.

XAY

XBF

Summary


- Sequencing update
 - July sequences (n=58) are from the Eastern Cape, KwaZulu-Natal, Gauteng, Mpumalanga, and the Western Cape. August sequences (n=167) are from all provinces except the Northern Cape and KwaZulu-Natal. September sequences (n=71) are from the Western Cape, Gauteng, Mpumalanga, and North West.

• Variant of Concern Omicron in South Africa

- Omicron dominated in July (100%), August (100%), and September (100%)
- XBB.1.5 constituted 38% of July, 31% of August and 27% of September sequences
- XBB.1.16 has been detected in July (17%), August (10%), and September (11%)
- XBB.1.9.* (clade 23D) was detected in sequences from July (16%), August (8%) and September (3%)
- Sixteen sequences of the EG.5.1.* lineage (clade 23F) have been detected in Gauteng (n=3) and the Western Cape (n=13) in July (n=7, 12%), August (n=5, 3%), and September (n=4, 6%)
- Thirty-nine sequences of the BA.2.86 lineage have been detected in Gauteng (n=20), Mpumalanga (n=8), Western Cape (n=6), North West (n=4), and Free State (n=1), in July (n=2, 3%), August (n=27, 16%), and September (n=10, 14%)



Spike protein mutation* profile of Variants of Interest and Concern




- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
 - Including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
 - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape

*Only mutations present in Omicron, Delta, or recombinant sequences are pictured



BA.2.86 and EG.5.1 spike mutations*

Frequency of spike SNVs for Omicron (21L/BA.2.86) n = 39



Mutation

University of Stellenbosch & NHLS Tygerberg Virology



Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga **Bronwyn Kleinhans** Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen **Diagnostic laboratory staff**

This project has

Horizon Europe

Research and

under grant No.

101046041

UKZN-Inkosi Albert Luthuli Central Hospital

UNIVERSITY OF INYUVES YAKWAZULU-NATALI

Dr Khanvi Msomi Dr Neli Ngcaba Dr Kerusha Govender Dr Tshepiso Mosito Dr Pravi Moodley Mr Malcolm Ellapen Dr Aabida Khan Mr Kubendran Reddy Dr Lili Gounder The COVID-19 Bench team Dr Kerri Francois Dr Cherise Naicker Dr Joedene Chetty

University of KwaZulu-Natal & Africa **Health Research Institute**



Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav **Emmanuel James San**

KRISP at UKZN:



National Institute for Communicable Diseases



Centre for Respiratory Diseases & Meningitis Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans Nicole Wolter

Mignon du Plessis Stefano Tempia Mvuyo Makhasi Cheryl Cohen

Sequencing Core Facility Zamantungwa Khumalo Annie Chan Morne du Plessis Stanford Kwenda Mushal Allam Florah Mnvameni





University of Cape Town, NHLS & Western Cape Government



NHLS Greenpoint Mary-Anne Davies Annabel Enoch Hannah Hussev Andrew Boulle Masudah Paleker

Theuns Jacobs Erna Morden



Nei-yuan Hsiao

Diana Hardie

Kruger Marais

Stephen Korsman

Ziyaad Valley-Omar

UCT. IDM and CIDRI-Africa

Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Nokuzola Mbhele Fezokuhle Khumalo Thabang Serakge Bruna Galvão Linda Boloko Arghavan Alisoltani (U. California)



centre infectious (AA EDCTP W Robert Wilkinson Darren Martin

Nicola Mulder Samrc Wendy Burgers Ntobeko Ntusi CAPE TOWN HVTN Rageema Joseph Sean Wasserman

> cience & innovation epartment: dense and knowation EPUBLIC OF SOUTH AFRICA

Zoonotic arbo and respiratory virus program **Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria**

> ZARV research program/UP Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist) Carien van Niekerk

NHLS Tshwane Prof Simnikiwe Mayaphi (HOD)

Funders:

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

Cathrine Scheepers Thandeka Movo

Sibongile Walaza



Phillip Senzo Mtshali











University of the

Free State

Dominique Goedhals

Emmanuel Ogunbayo

Makgotso Maotoana

NHLS Division of Virology

Diagnostic laboratory staff

Lutfiyya Mohamed

Sabeehah Vawda

Thokozani Mkhize

Felicity Burt

Armand Bester

Martin Myaga

Peter Mwangi

Milton Mogotsi

UNIVERSITY OF THE FREE STATE UNIVERSITEIT VAN DIE VRYSTAAT YUNIVESITHI Y FREISTA'

UFS

Centre for HIV and STIs **Jinal Bhiman**

Constantinos Kurt Wibmer Tandile Hermanus Frances Ayres Zanele Molaudzi Bronwen Lambson **Tandile Hermanus**

Prudence Kgagudi

Brent Oosthuysen

Penny Moore







NICD Groups

NICD COVID-19 response team NICD SARS-CoV-2 Sequencing
















Lynn Morris

Arshad Ismail





HYRAX CAPE TOWN HVTN PATHOLOGISTS



Hyrax Biosciences

AMPATH LABORATORIES

Key to Diagnostic Excellence







NHLS Koleka Mlisana Kathleen Subramoney Oluwakemi Laguda-Akingba

Jeannette Wadula

Simon Travers

Cape Town HVTN Laboratory Erica Anderson-Nissen Anneta Naidoo

Ndlovu Research **Hugo Tempelman** CJ Umunnakwe

Lancet Allison J. Glass **Raquel Viana**

Ampath Terry Marshall **Cindy van Deventer** Eddie Silberbauer

Pathcare Vermaak Andries Drever Howard Newman **Riaan Writes** Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

Cytespace Africa Laboratories Christa Viljoen

ARC-OVI Lia Rotherham CAPRISA Salim Abdool Karim Nigel Garret

Additional support and collaborators

UKZN - Big Data Francesco Pettruccione Ilya Sinayskiy

University of Oxford José Lourenço

FioCruz, Brazil Vagner Fonseca Marta Giovanetti Luiz Carlos Junior Alcantara Africa CDC and Africa PGI John Nkengasong Sofonias Tessema

Netcare **Richard Friedland** Craig Murphy Caroline Maslo Liza Sitharam

DSI

Glaudina Loots

SA MRC **Glenda Gray**

Pathcare N1 City Jean Maritz Nadine Cronje Petra Raimond Kim Hoek























NATIONAL HEALTH LABORATORY SERVICE

XX


ЕDСТР

3030) is part of the

European Union"

EDCTP2 programme supported by the

South African genomes submitted per submitting lab, 2020 - 2023 (N= 53 577)



NGS-SA Labs

CERI: Centre for Epidemic Response and Innovation **KRISP:** KZN Research Innovation and Sequencing Platform NDLOVU: Ndlovu Research Laboratories **NICD**: National Institute for Communicable Diseases **NHLS**: National Health Laboratory Service **SU**: Stellenbosch University **UCT**: University of Cape Town **UFS**: University of the Free State **UP**: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.



Currently circulating Variants of Interest (VOI) as of 09 Aug 2023

Pango lineage	Nextstrain clade	Genetic features	Earliest documented samples	Date of designation and risk assessments
XBB.1.5	23A	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1, with a breakpoint in S1. XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.9.1)	21-10-2022	11-01-2023 XBB.1.5 Rapid Risk Assessment, 11 January 2023 XBB.1.5 Updated Rapid Risk Assessment, 25 January 2023 XBB.1.5 Updated Risk Assessment, 24 February 2023 XBB.1.5 Updated Risk Assessment, 20 June 2023
XBB.1.16	23В	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1 XBB.1 + S:E180V, S:K478R and S:F486P	09-01-2023	17-04-2023 XBB.1.16 Initial Risk Assessment, 17 April 2023 XBB.1.16 Updated Risk Assessment, 05 June 2023
EG.5	Not assigned	XBB.1.9.2 + S:F456L Includes EG.5.1: EG.5 + S:Q52H	17-02-2023	09-08-2023 EG.5 Initial Risk Evaluation, 09 August 2023

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 11 Aug 2023

Currently circulating variants under monitoring (VUMs)

Pango lineage [#] (+ mutation)	Nextstrain clade	Spike genetic features	Earliest documented samples	Date of designation and risk assessments
BA.2.75	22D	BA.2 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:D339H, S:G446S, S:N460K, S:Q493R reversion	31-12-2021	06-07-2022
CH.1.1	22D	BA.2.75 + S:L452R, S:F486S	27-07-2022	08-02-2023
BQ.1	22E	BA.5 + S:R346T, S:K444T, S:N460K	07-02-2022	21-09-2022
XBB*	22F	BA.2+ S:V83A, S:Y144-, S:H146Q, S:Q183E, S:V213E, S:G252V, S:G339H, S:R346T, S:L368I, S:V445P, S:G446S, S:N460K, S:F486S, S:F490S	13-08-2022	12-10-2022
XBB.1.9.1	23D	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1 XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.5)	05-12-2022	30-03-2022
XBB.1.9.2	23D	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1 XBB.1 + S:F486P, S:Q613H	05-12-2022	26-04-2023
XBB.2.3	22E	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1 XBB + S:D253G, S:F486P, S:P521S	09-12-2022	17-05-2023
BA.2.86	Not assigned	Mutations relative to putative ancestor BA.2	24-07-2023	17-08-2023

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 24 Aug 2023

Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)